Incidence, severity and treatment outcome of tuberculosis in the era of the COVID-19 pandemic, France, 2018-2023.

Introduction: In France, the average steady decline in tuberculosis (TB) incidence close to 5 % per year over the past half-century has been occasionally interrupted by disruptions related to external events. We describe the impact of the COVID-19 pandemic on TB incidence, severity and treatment outcome.

Methods: We analysed the number of TB cases and treatment outcomes reported through the mandatory notification system through 2018-2023.

[Epidemiology of burns in mayotte in 2022: an exhaustive study on a particular health area].

The last French department, created in 2011, Mayotte still lacks its integration into official health statistics, making it difficult to adapt care facilities to needs, as well as planning for prevention. We conducted a retrospective epidemiological study including all patients treated in the Mayotte burns unit between February 1, 2022 and January 31, 2023 (339 patients). We first studied burn patients on the island, i.

Ultrasonication coupled to enzymatic hydrolysis of soybean okara proteins for producing bioactive and bioavailable peptides.

This work was aimed to explore the antioxidative properties, bioavailability and the safety of bioactive peptides obtained by the enzymatic hydrolysis of ultrasound-treated (UO) and untreated (nUO) soybean okara proteins. Particularly, the peptidomic profiles of both hydrolysates were examined using an untargeted metabolomics technique for suspect screening that was specifically designed for the profiling of short-chain peptides and relied on ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) and bioinformatics. Next, both UO and nUO hydrolysates reduce Dipeptidyl peptidase-IV (DPP-IV) enzyme activity until 39.